[皮肤黑色素瘤的免疫疗法--2022 年更新]。

Q4 Medicine Magyar onkologia Pub Date : 2022-06-20 Epub Date: 2022-06-06

Judit Oláh

{"title":"[皮肤黑色素瘤的免疫疗法--2022 年更新]。","authors":"Judit Oláh","doi":"","DOIUrl":null,"url":null,"abstract":"Melanoma treatment has been revolutionized during the last decade. Currently first line therapeutic options for advanced melanoma include immunotherapy with anti-PD-1 antibodies (combination of PD-1 and CTLA-4 blockers should be an option in a selected group of patients) or targeted therapy with BRAF and MEK inhibitors in BRAF V600 mutated tumors. This review aims to summarize long-term survival data of immunotherapy in cutaneous melanoma and to show possible directions of development in combined oncological modalities.","PeriodicalId":18175,"journal":{"name":"Magyar onkologia","volume":"66 2","pages":"119-124"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[mmunotherapy of cutaneous melanoma - update 2022].\",\"authors\":\"Judit Oláh\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Melanoma treatment has been revolutionized during the last decade. Currently first line therapeutic options for advanced melanoma include immunotherapy with anti-PD-1 antibodies (combination of PD-1 and CTLA-4 blockers should be an option in a selected group of patients) or targeted therapy with BRAF and MEK inhibitors in BRAF V600 mutated tumors. This review aims to summarize long-term survival data of immunotherapy in cutaneous melanoma and to show possible directions of development in combined oncological modalities.\",\"PeriodicalId\":18175,\"journal\":{\"name\":\"Magyar onkologia\",\"volume\":\"66 2\",\"pages\":\"119-124\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Magyar onkologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/6/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Magyar onkologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

过去十年间，黑色素瘤的治疗发生了翻天覆地的变化。目前，晚期黑色素瘤的一线治疗方案包括使用抗PD-1抗体的免疫疗法（PD-1和CTLA-4阻断剂的联合疗法应在特定患者群体中使用），或使用BRAF和MEK抑制剂对BRAF V600突变肿瘤进行靶向治疗。本综述旨在总结皮肤黑色素瘤免疫疗法的长期生存数据，并指出联合肿瘤疗法的可能发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[mmunotherapy of cutaneous melanoma - update 2022].

Melanoma treatment has been revolutionized during the last decade. Currently first line therapeutic options for advanced melanoma include immunotherapy with anti-PD-1 antibodies (combination of PD-1 and CTLA-4 blockers should be an option in a selected group of patients) or targeted therapy with BRAF and MEK inhibitors in BRAF V600 mutated tumors. This review aims to summarize long-term survival data of immunotherapy in cutaneous melanoma and to show possible directions of development in combined oncological modalities.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Magyar onkologia Medicine-Medicine (all)

CiteScore

0.60

自引率

0.00%

发文量